Health

Add as a preferred source on Google

UK Regulator Announces Women’s Health Programme After Trial Evidence Gaps

An analysis of 4,616 initial submissions found pregnant women represented in 1.1% and breastfeeding women in 0.6%.

Updated 2 min read
A clinician speaks with a patient in a reproductive health clinic in London, United Kingdom. / EconoTimes.ai (mono)
A clinician speaks with a patient in a reproductive health clinic in London, United Kingdom. / EconoTimes.ai (mono)

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) announced a Women’s Health Programme on Nov. 16 to address gaps in evidence on medicines and medical devices used by women and support innovation. The initiative concerns evidence on how products may affect women, including during pregnancy and across reproductive health.

A peer-reviewed study by the MHRA and the University of Liverpool examined 4,616 initial submissions to the agency’s Clinical Trials Unit for investigational medicinal product trials. The submissions arrived between Feb. 23, 2019, and Oct. 31, 2023. Pregnant women were represented in 1.1% of submissions and breastfeeding women in 0.6%.

Both sexes appeared in 90% of the submissions; 3.7% covered women only and 6.1% men only. Those percentages describe submissions, not the share of individual trial participants who were pregnant or breastfeeding.

The MHRA says research has left gaps in evidence about medicines and devices in pregnancy and other areas of reproductive health. The agency says responses to medical products can vary with biological factors and circumstances such as age, pregnancy and other health conditions. It plans to bring patients, researchers, health professionals and industry together, and to work with researchers and innovators early. The regulator says its safety, quality and effectiveness standards will remain in place.

“Better evidence can help us understand where important differences exist,” MHRA Chief Executive Lawrence Tallon said. The programme is the regulator’s contribution to the renewed Women’s Health Strategy for England, published in April 2026, alongside related work in Scotland, Wales and Northern Ireland.

A related MHRA and Health Research Authority pilot tested Inclusion and Diversity Plans with seven studies in 2025. The agencies plan to invite more researchers and sponsors into a 12-month phase starting in early 2027; submitting a plan is not a legal requirement. The MHRA has scheduled an introductory webinar for Dec. 9. Its announcement did not set a programme budget, numerical targets or a timetable for measuring progress.

Related articles

View all